As of August this year, based on Biogen's most recent financial report, the company's trailing twelve months EPS is $5.68. During 2025, BIIB reported a per-share earnings of $8.83, which shows a decrease compared to the EPS of $11.21 recorded in 2024. Biogen's EPS for the quarterly period ending on Jun 30, 2026 came in at $0.66.
The yearly earnings per share during 2025 was $8.83, a decrease of 21.2% compared to $11.21 recorded in 2024. Over the quarter ending Jun 30, 2026, the earnings per share came in at $0.66, reflecting a 84.8% decline compared to the same quarter a year earlier. As of June 2026, the TTM EPS is $5.68. During 2024, the annual earnings per share was $11.21, representing an increase of 39.8% compared to 2023.
Over the past 12 months, Biogen has recorded an earnings per share growth rate of -84.8% (YoY, quarterly). Over an extended period, the company recorded an average EPS annual growth rate of -25% per year for the last 3 years. In the last five years, the company had an average annual EPS growth of -18.7%. A ten-year view shows that BIIB has seen an average earnings per share growth of -5.4% per year.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| GILD Gilead Sciences Inc | 17.45 | 1,700% | 23.2% | 132.8% |
| PFE Pfizer Inc | 19.07 | -3.5% | -37.4% | -3.7% |
| QGEN Qiagen NV | 22.7 | 415.8% | 1.8% | 3.9% |
| AMGN AMGEN Inc | 26.39 | 88.1% | 5.6% | 2.9% |
| JNJ Johnson & Johnson | 28.89 | 90.6% | 17.7% | 14.8% |
| BIIB Biogen Inc | 35.69 | -21.2% | -25% | -18.7% |
| ILMN Illumina Inc | 38.07 | 171.1% | N/A | 4.1% |
| BIO Bio-Rad Laboratories Inc - Class A | 56.95 | 142.6% | N/A | -26.3% |
| ABBV Abbvie Inc | 121.21 | -1.3% | -29.1% | -2.8% |
All data is based on quarterly TTM periods, unless otherwise specified.